Parkinson's disease

Goetz, 2011, The history of Parkinson's disease: early clinical descriptions and neurological therapies, Cold Spring Harb Perspect Med, 1, a008862, 10.1101/cshperspect.a008862

Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745

Marras, 2013, Parkinson's disease subtypes: lost in translation?, J Neurol Neurosurg Psychiatry, 84, 409, 10.1136/jnnp-2012-303455

Jankovic, 1990, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology, 40, 1529, 10.1212/WNL.40.10.1529

Khoo, 2013, The spectrum of nonmotor symptoms in early Parkinson disease, Neurology, 80, 276, 10.1212/WNL.0b013e31827deb74

Martinez-Martin, 2011, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, 26, 399, 10.1002/mds.23462

Duncan, 2014, Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms, Mov Disord, 29, 195, 10.1002/mds.25664

Postuma, 2012, Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease, Mov Disord, 27, 617, 10.1002/mds.24996

2005

Aurora, 2010, Best practice guide for the treatment of REM sleep behavior disorder (RBD), J Clin Sleep Med, 6, 85, 10.5664/jcsm.27717

Postuma, 2009, Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder, Neurology, 72, 1296, 10.1212/01.wnl.0000340980.19702.6e

Schenck, 2013, Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series, Sleep Med, 14, 744, 10.1016/j.sleep.2012.10.009

Iranzo, 2013, Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study, Lancet Neurol, 12, 443, 10.1016/S1474-4422(13)70056-5

Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann Neurol, 72, 893, 10.1002/ana.23687

Siderowf, 2012, Premotor Parkinson's disease: concepts and definitions, Mov Disord, 27, 608, 10.1002/mds.24954

Hely, 2005, Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years, Mov Disord, 20, 190, 10.1002/mds.20324

Hely, 2008, The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years, Mov Disord, 23, 837, 10.1002/mds.21956

Coelho, 2012, Late-stage Parkinson disease, Nat Rev Neurol, 8, 435, 10.1038/nrneurol.2012.126

Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03

2014, 2014 Alzheimer's disease facts and figures, Alzheimers Dement, 10, e47

Von Campenhausen, 2005, Prevalence and incidence of Parkinson's disease in Europe, Eur Neuropsychopharmacol, 15, 473, 10.1016/j.euroneuro.2005.04.007

Strickland, 2004, Parkinson's prevalence estimated by a state registry, Mov Disord, 19, 318, 10.1002/mds.10619

Bauso, 2012, Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina, Eur J Neurol, 19, 1108, 10.1111/j.1468-1331.2012.03683.x

Okubadejo, 2006, Parkinson's disease in Africa: a systematic review of epidemiologic and genetic studies, Mov Disord, 21, 2150, 10.1002/mds.21153

Muangpaisan, 2009, Systematic review of the prevalence and incidence of Parkinson's disease in Asia, J Epidemiol, 19, 281, 10.2188/jea.JE20081034

Benamer, 2008, Parkinson's disease in Arabs: a systematic review, Mov Disord, 23, 1205, 10.1002/mds.22041

Van Den Eeden, 2003, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity, Am J Epidemiol, 157, 1015, 10.1093/aje/kwg068

De Lau, 2006, Epidemiology of Parkinson's disease, Lancet Neurol, 5, 525, 10.1016/S1474-4422(06)70471-9

Driver, 2009, Incidence and remaining lifetime risk of Parkinson disease in advanced age, Neurology, 72, 432, 10.1212/01.wnl.0000341769.50075.bb

Pringsheim, 2014, The prevalence of Parkinson's disease: a systematic review and meta-analysis, Mov Disord, 29, 1583, 10.1002/mds.25945

Ritz, 2014, Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease, Neurology, 83, 1396, 10.1212/WNL.0000000000000879

Cipriani, 2010, Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis, Biomark Med, 4, 701, 10.2217/bmm.10.94

Mortimer, 2012, Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis, Neurology, 79, 1174, 10.1212/WNL.0b013e3182698ced

Foubert-Samier, 2012, Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort, Neurology, 79, 1615, 10.1212/WNL.0b013e31826e25ce

Goldman, 2012, Solvent exposures and Parkinson disease risk in twins, Ann Neurol, 71, 776, 10.1002/ana.22629

Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045

Corti, 2011, What genetics tells us about the causes and mechanisms of Parkinson's disease, Physiol Rev, 91, 1161, 10.1152/physrev.00022.2010

Sidransky, 2012, The link between the GBA gene and parkinsonism, Lancet Neurol, 11, 986, 10.1016/S1474-4422(12)70190-4

Sidransky, 2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, N Engl J Med, 361, 1651, 10.1056/NEJMoa0901281

Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease, Nat Genet, 46, 989, 10.1038/ng.3043

Lee, 2012, Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease, Neurology, 79, 2061, 10.1212/WNL.0b013e3182749f28

Popat, 2011, Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease, Eur J Neurol, 18, 756, 10.1111/j.1468-1331.2011.03353.x

Hamza, 2011, Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee, Plos Genet, 7, e1002237, 10.1371/journal.pgen.1002237

Goldman, 2012, Head injury, alpha-synuclein Rep1, and Parkinson's disease, Ann Neurol, 71, 40, 10.1002/ana.22499

Dickson, 2009, Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria, Lancet Neurol, 8, 1150, 10.1016/S1474-4422(09)70238-8

Kordower, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, 136, 2419, 10.1093/brain/awt192

Dickson, 2012, Parkinson's disease and parkinsonism: neuropathology, Cold Spring Harb Perspect Med, 2, a009258, 10.1101/cshperspect.a009258

Masters, 2011, Overview and recent advances in neuropathology. Part 2: Neurodegeneration, Pathology, 43, 93, 10.1097/PAT.0b013e3283426eee

Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166

Goedert, 2012, 100 years of Lewy pathology, Nat Rev Neurol, 9, 13, 10.1038/nrneurol.2012.242

Iwanaga, 1999, Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases, Neurology, 52, 1269, 10.1212/WNL.52.6.1269

Fumimura, 2007, Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease, J Neuropathol Exp Neurol, 66, 354, 10.1097/nen.0b013e3180517454

Beach, 2010, Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders, Acta Neuropathol, 119, 689, 10.1007/s00401-010-0664-3

Del Tredici, 2010, Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease, Acta Neuropathol, 119, 703, 10.1007/s00401-010-0665-2

Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9

Selikhova, 2009, A clinico-pathological study of subtypes in Parkinson's disease, Brain, 132, 2947, 10.1093/brain/awp234

Kempster, 2010, Relationships between age and late progression of Parkinson's disease: a clinico-pathological study, Brain, 133, 1755, 10.1093/brain/awq059

Irwin, 2012, Neuropathologic substrates of Parkinson disease dementia, Ann Neurol, 72, 587, 10.1002/ana.23659

Parkkinen, 2008, Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance, Acta Neuropathol, 115, 399, 10.1007/s00401-008-0346-6

Halliday, 2008, The progression of pathology in longitudinally followed patients with Parkinson's disease, Acta Neuropathol, 115, 409, 10.1007/s00401-008-0344-8

Saito, 2003, Accumulation of phosphorylated alpha-synuclein in aging human brain, J Neuropathol Exp Neurol, 62, 644, 10.1093/jnen/62.6.644

Kovacs, 2012, An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology, Acta Neuropathol, 124, 37, 10.1007/s00401-012-0964-x

Schulz-Schaeffer, 2010, The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia, Acta Neuropathol, 120, 131, 10.1007/s00401-010-0711-0

Cremades, 2012, Direct observation of the interconversion of normal and toxic forms of α-synuclein, Cell, 149, 1048, 10.1016/j.cell.2012.03.037

Kalia, 2013, α-Synuclein oligomers and clinical implications for Parkinson disease, Ann Neurol, 73, 155, 10.1002/ana.23746

Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, 134, 1493, 10.1093/brain/awr031

Irwin, 2013, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nat Rev Neurosci, 14, 626, 10.1038/nrn3549

Doherty, 2013, Parkin disease: a clinicopathologic entity?, JAMA Neurol, 70, 571, 10.1001/jamaneurol.2013.172

Poulopoulos, 2012, The neuropathology of genetic Parkinson's disease, Mov Disord, 27, 831, 10.1002/mds.24962

Kalia, 2015, Clinical correlations with Lewy body pathology in LRRK2-related Parkinson's disease, JAMA Neurol, 72, 100, 10.1001/jamaneurol.2014.2704

Tansey, 2010, Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention, Neurobiol Dis, 37, 510, 10.1016/j.nbd.2009.11.004

Phani, 2012, Neurodegeneration and inflammation in Parkinson's disease, Parkinsonism Relat Disord, 18, S207, 10.1016/S1353-8020(11)70064-5

Devine, 2011, Parkinson's disease and alpha-synuclein expression, Mov Disord, 26, 2160, 10.1002/mds.23948

Cookson, 2012, Cellular effects of LRRK2 mutations, Biochem Soc Trans, 40, 1070, 10.1042/BST20120165

Dzamko, 2012, An emerging role for LRRK2 in the immune system, Biochem Soc Trans, 40, 1134, 10.1042/BST20120119

Lee, 2012, The synaptic function of LRRK2, Biochem Soc Trans, 40, 1047, 10.1042/BST20120113

Sanna, 2012, LRRK2 and vesicle trafficking, Biochem Soc Trans, 40, 1117, 10.1042/BST20120117

Martin, 2014, Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease, Cell, 157, 472, 10.1016/j.cell.2014.01.064

Paisán-Ruíz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023

Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study, Lancet Neurol, 7, 583, 10.1016/S1474-4422(08)70117-0

Aasly, 2010, Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease, Mov Disord, 25, 2156, 10.1002/mds.23265

Ozelius, 2006, LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews, N Engl J Med, 354, 424, 10.1056/NEJMc055509

Lesage, 2006, LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs, N Engl J Med, 354, 422, 10.1056/NEJMc055540

Zimprich, 2011, A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease, Am J Hum Genet, 89, 168, 10.1016/j.ajhg.2011.06.008

Vilariño-Güell, 2011, VPS35 mutations in Parkinson disease, Am J Hum Genet, 89, 162, 10.1016/j.ajhg.2011.06.001

Chartier-Harlin, 2011, Translation initiator EIF4G1 mutations in familial Parkinson disease, Am J Hum Genet, 89, 398, 10.1016/j.ajhg.2011.08.009

Vilariño-Güell, 2014, DNAJC13 mutations in Parkinson disease, Hum Mol Genet, 23, 1794, 10.1093/hmg/ddt570

Funayama, 2015, CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study, Lancet Neurol, 14, 274, 10.1016/S1474-4422(14)70266-2

Bonifacino, 2008, Retromer, Curr Opin Cell Biol, 20, 427, 10.1016/j.ceb.2008.03.009

Tucci, 2012, Study of the genetic variability in a Parkinson's Disease gene: EIF4G1, Neurosci Lett, 518, 19, 10.1016/j.neulet.2012.04.033

Schulte, 2012, Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease, Neurogenetics, 13, 281, 10.1007/s10048-012-0334-9

Schrag, 2006, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, Lancet Neurol, 5, 355, 10.1016/S1474-4422(06)70411-2

Lücking, 2000, Association between early-onset Parkinson's disease and mutations in the parkin gene, N Engl J Med, 342, 1560, 10.1056/NEJM200005253422103

Periquet, 2003, Parkin mutations are frequent in patients with isolated early-onset parkinsonism, Brain, 126, 1271, 10.1093/brain/awg136

Singleton, 2013, The genetics of Parkinson's disease: progress and therapeutic implications, Mov Disord, 28, 14, 10.1002/mds.25249

Klein, 2007, Deciphering the role of heterozygous mutations in genes associated with parkinsonism, Lancet Neurol, 6, 652, 10.1016/S1474-4422(07)70174-6

Mccoy, 2012, Mitochondrial quality control and dynamics in Parkinson's disease, Antioxid Redox Signal, 16, 869, 10.1089/ars.2011.4019

Puschmann, 2013, Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations, Parkinsonism Relat Disord, 19, 407, 10.1016/j.parkreldis.2013.01.020

Krebs, 2013, The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures, Hum Mutat, 34, 1200, 10.1002/humu.22372

Quadri, 2013, Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism, Hum Mutat, 34, 1208, 10.1002/humu.22373

Wilson, 2014, Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology, Am J Hum Genet, 95, 729, 10.1016/j.ajhg.2014.10.015

Butcher, 2013, Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications, JAMA Neurol, 70, 1359, 10.1001/jamaneurol.2013.3646

Trinh, 2013, Advances in the genetics of Parkinson disease, Nat Rev Neurol, 9, 445, 10.1038/nrneurol.2013.132

Bezard, 2011, A tale on animal models of Parkinson's disease, Mov Disord, 26, 993, 10.1002/mds.23696

Hawkes, 2007, Parkinson's disease: a dual-hit hypothesis, Neuropathol Appl Neurobiol, 33, 599, 10.1111/j.1365-2990.2007.00874.x

Kordower, 2008, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease, Nat Med, 14, 504, 10.1038/nm1747

Kordower, 2008, Transplanted dopaminergic neurons develop PD pathologic changes: a second case report, Mov Disord, 23, 2303, 10.1002/mds.22369

Li, 2008, Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation, Nat Med, 14, 501, 10.1038/nm1746

Visanji, 2013, The prion hypothesis in Parkinson's disease: Braak to the future, Acta Neuropathol Commun, 1, 2, 10.1186/2051-5960-1-2

Luk, 2012, Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice, J Exp Med, 209, 975, 10.1084/jem.20112457

Luk, 2012, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, 338, 949, 10.1126/science.1227157

Masuda-Suzukake, 2013, Prion-like spreading of pathological α-synuclein in brain, Brain, 136, 1128, 10.1093/brain/awt037

Sacino, 2013, Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein, Acta Neuropathol Commun, 1, 38, 10.1186/2051-5960-1-38

Recasens, 2014, Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys, Ann Neurol, 75, 351, 10.1002/ana.24066

Surmeier, 2012, Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease, J Biol Chem, 288, 10736, 10.1074/jbc.R112.410530

Chen, 2012, Urate in Parkinson's disease: more than a biomarker?, Curr Neurol Neurosci Rep, 12, 367, 10.1007/s11910-012-0282-7

Greenamyre, 2004, Biomedicine. Parkinson's—divergent causes, convergent mechanisms, Science, 304, 1120, 10.1126/science.1098966

Sian-Hülsmann, 2011, The relevance of iron in the pathogenesis of Parkinson's disease, J Neurochem, 118, 939, 10.1111/j.1471-4159.2010.07132.x

Hughes, 2001, Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease, Neurology, 57, 1497, 10.1212/WNL.57.8.1497

Gelb, 1999, Diagnostic criteria for Parkinson disease, Arch Neurol, 56, 33, 10.1001/archneur.56.1.33

Berg, 2013, Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities, Lancet Neurol, 12, 514, 10.1016/S1474-4422(13)70047-4

Berg, 2014, Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease, Mov Disord, 29, 454, 10.1002/mds.25844

2000, Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group, JAMA, 284, 1931, 10.1001/jama.284.15.1931

Fahn, 2004, Levodopa and the progression of Parkinson's disease, N Engl J Med, 351, 2498, 10.1056/NEJMoa033447

2007, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease, Neurology, 69, 1480, 10.1212/01.wnl.0000277648.63931.c0

Whone, 2003, Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study, Ann Neurol, 54, 93, 10.1002/ana.10609

Brooks, 2011, Imaging biomarkers in Parkinson's disease, Prog Neurobiol, 95, 614, 10.1016/j.pneurobio.2011.08.009

Marek, 2014, Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, Neurology, 82, 1791, 10.1212/WNL.0000000000000424

Kraemmer, 2014, Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts, Mov Disord, 29, 1767, 10.1002/mds.25975

Salsone, 2012, Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder, Mov Disord, 27, 1068, 10.1002/mds.25002

Iranzo, 2014, Neuropathology of prodromal Lewy body disease, Mov Disord, 29, 410, 10.1002/mds.25825

Lehéricy, 2012, Magnetic resonance imaging of the substantia nigra in Parkinson's disease, Mov Disord, 27, 822, 10.1002/mds.25015

Cochrane, 2013, Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis, Neurology, 80, 857, 10.1212/WNL.0b013e318284070c

Lehéricy, 2014, 7 tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease, Mov Disord, 29, 1574, 10.1002/mds.26043

Visanji, 2014, Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker, Mov Disord, 29, 444, 10.1002/mds.25789

Shannon, 2012, Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases, Mov Disord, 27, 716, 10.1002/mds.25020

Böttner, 2012, Expression pattern and localization of alpha-synuclein in the human enteric nervous system, Neurobiol Dis, 48, 474, 10.1016/j.nbd.2012.07.018

Gold, 2013, Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease, Mov Disord, 28, 237, 10.1002/mds.25298

Visanji, 2015, Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease, Neurology, 84, 609, 10.1212/WNL.0000000000001240

Donadio, 2014, Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease, Neurology, 82, 1362, 10.1212/WNL.0000000000000316

Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008

Parnetti, 2013, Cerebrospinal fluid biomarkers in Parkinson disease, Nat Rev Neurol, 9, 131, 10.1038/nrneurol.2013.10

Eller, 2009, Biological fluid biomarkers in neurodegenerative parkinsonism, Nat Rev Neurol, 5, 561, 10.1038/nrneurol.2009.135

Stewart, 2014, Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control, Neurobiol Aging, 35, 418, 10.1016/j.neurobiolaging.2013.08.008

Bogdanov, 2008, Metabolomic profiling to develop blood biomarkers for Parkinson's disease, Brain, 131, 389, 10.1093/brain/awm304

Shi, 2011, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann Neurol, 69, 570, 10.1002/ana.22311

Aldakheel, 2014, Pathogenesis-targeted, disease-modifying therapies in Parkinson disease, Neurother, 11, 6, 10.1007/s13311-013-0218-1

Tran, 2014, α-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration, Cell Rep, 7, 2054, 10.1016/j.celrep.2014.05.033

Coune, 2012, Parkinson's disease: gene therapies, Cold Spring Harb Perspect Med, 2, a009431, 10.1101/cshperspect.a009431

Kordower, 2013, Trophic factor gene therapy for Parkinson's disease, Mov Disord, 28, 96, 10.1002/mds.25344

Bjorklund, 2013, Cell therapy for Parkinson's disease: what next?, Mov Disord, 28, 110, 10.1002/mds.25343

Lindvall, 2013, Developing dopaminergic cell therapy for Parkinson's disease—give up or move forward?, Mov Disord, 28, 268, 10.1002/mds.25378

Charles, 2014, Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease, Parkinsonism Relat Disord, 20, 731, 10.1016/j.parkreldis.2014.03.019

Fox, 2011, The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease, Mov Disord, 26, S2, 10.1002/mds.23829

Connolly, 2014, Pharmacological treatment of Parkinson's disease: a review, JAMA, 311, 1670, 10.1001/jama.2014.3654

2014, Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, Lancet, 384, 1196, 10.1016/S0140-6736(14)60683-8

Lang, 2014, Initiating dopaminergic treatment in Parkinson's disease, Lancet, 384, 1164, 10.1016/S0140-6736(14)60962-4

Hauser, 2013, Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial, Lancet Neurol, 12, 346, 10.1016/S1474-4422(13)70025-5

Olanow, 2014, Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study, Lancet Neurol, 13, 141, 10.1016/S1474-4422(13)70293-X

Kalia, 2013, Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials, Mov Disord, 28, 131, 10.1002/mds.25273

Honigfeld, 1998, Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry, J Clin Psychiatry, 59, 3

Burn, 2006, Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease, Mov Disord, 21, 1899, 10.1002/mds.21077

Cummings, 2014, Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial, Lancet, 383, 533, 10.1016/S0140-6736(13)62106-6

Seppi, 2011, The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease, Mov Disord, 26, S42, 10.1002/mds.23884

Richard, 2012, A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease, Neurology, 78, 1229, 10.1212/WNL.0b013e3182516244

Barone, 2010, Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial, Lancet Neurol, 9, 573, 10.1016/S1474-4422(10)70106-X

Yarnall, 2011, The interplay of cholinergic function, attention, and falls in Parkinson's disease, Mov Disord, 26, 2496, 10.1002/mds.23932

Emre, 2004, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med, 351, 2509, 10.1056/NEJMoa041470

Chung, 2010, Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease, Neurology, 75, 1263, 10.1212/WNL.0b013e3181f6128c

Henderson, 2013, The respond trial—rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen, BMC Neurol, 13, 188, 10.1186/1471-2377-13-188

Kalia, 2013, Deep brain stimulation for Parkinson's disease and other movement disorders, Curr Opin Neurol, 26, 374, 10.1097/WCO.0b013e3283632d08

Fasano, 2012, Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation, Lancet Neurol, 11, 429, 10.1016/S1474-4422(12)70049-2

Schuepbach, 2013, Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, 368, 610, 10.1056/NEJMoa1205158